New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
ApexOnco Front Page
Recent articles
Three off-the-shelf mRNA therapies join intismeran autogene.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
At least 15 dual-payload ADCs will be discussed.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
